These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1626552)

  • 1. Quality of life and hematocrit level.
    Levin NW
    Am J Kidney Dis; 1992 Jul; 20(1 Suppl 1):16-20. PubMed ID: 1626552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin and the quality of life of end-stage renal disease patients: a comparative analysis.
    Evans RW
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):62-70. PubMed ID: 1928082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on the improvement of quality of life with epoetin alfa therapy.
    Lundin AP; Delano BG; Quinn-Cefaro R
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):22S-26S. PubMed ID: 2345708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients.
    Delano BG
    Am J Kidney Dis; 1989 Aug; 14(2 Suppl 1):14-8. PubMed ID: 2757025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life: subjective and objective improvements with recombinant human erythropoietin therapy.
    Lundin AP
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):22-9. PubMed ID: 2648517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life.
    Nissenson AR
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):25-31. PubMed ID: 2669083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of recombinant human erythropoietin in hemodialysis patients.
    Mohini R
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):16-21. PubMed ID: 2648516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In search of an optimal hematocrit level in dialysis patients: rehabilitation and quality-of-life implications.
    Paganini EP
    Am J Kidney Dis; 1994 Jul; 24(1 Suppl 1):S10-6; discussion S31-2. PubMed ID: 8023833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring considerations in recombinant human erythropoietin therapy.
    Ogden DA
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):12-5. PubMed ID: 2669080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary study of the effects of correction of anemia with recombinant human erythropoietin therapy on sleep, sleep disorders, and daytime sleepiness in hemodialysis patients (The SLEEPO study).
    Benz RL; Pressman MR; Hovick ET; Peterson DD
    Am J Kidney Dis; 1999 Dec; 34(6):1089-95. PubMed ID: 10585319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
    Acharya VN; Sinha DK; Almeida AF; Pathare AV
    J Assoc Physicians India; 1995 Aug; 43(8):539-42. PubMed ID: 8772973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N; Sriuranpong V; Suwanrusme H
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Who should receive recombinant human erythropoietin?
    Van Stone JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):3-7. PubMed ID: 2669084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The quality of life of dialysis patients treated with recombinant human erythropoietin.
    Auer J; Oliver DO; Winearls CG
    Scand J Urol Nephrol Suppl; 1990; 131():61-5. PubMed ID: 2075472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epoetin: human recombinant erythropoietin.
    Flaharty KK; Grimm AM; Vlasses PH
    Clin Pharm; 1989 Nov; 8(11):769-82. PubMed ID: 2680241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recombinant human erythropoietin in the treatment of anemia associated with lymphoproliferative diseases--chronic lymphadenosis and multiple myeloma].
    Haber J; Spicka I; Petruzelka L; Kolesková E; Straub J; Jonásová A; Pospísilová B
    Vnitr Lek; 1996 Apr; 42(4):262-7. PubMed ID: 8693713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin in predialysis patients.
    Lim VS
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):34-7. PubMed ID: 1928077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.